Clinicopathological Analysis of HIF-1alpha and TERT on Survival Outcome in Glioblastoma Patients: A Prospective, Single Institution Study.
HIF-1α
IDH1
TERT
glioblastoma
hypoxia
immunohistochemistry
Journal
Journal of Cancer
ISSN: 1837-9664
Titre abrégé: J Cancer
Pays: Australia
ID NLM: 101535920
Informations de publication
Date de publication:
2019
2019
Historique:
received:
07
01
2019
accepted:
28
03
2019
entrez:
2
7
2019
pubmed:
2
7
2019
medline:
2
7
2019
Statut:
epublish
Résumé
Glioblastoma multiforme is a highly malignant and aggressive primary brain tumor with a dismal prognosis. We studied the association of immunohistochemical expression of hypoxia inducible factor-1 alpha (HIF-1α), telomerase reverse transcriptase (TERT), isocitrate dehydrogenase 1 (IDH1) and tumor protein p53 with overall survival (OS) in glioblastoma patients uniformly treated by standard of care, with adequate follow-up. In 87 patient samples studied, 59 were male and 28 were female. The median age was 55 years. The median follow-up was 27.7 months and the median overall survival was 14.9 months. Nuclear staining of HIF-1α was expressed in all samples and scored as strong in 42 (48%) and weak in 45 (52%). Multivariable Cox regression revealed strong HIF-1α expression as an independent poor prognostic factor (Hazard Ratio 2.12, 95% CI 1.20 - 3.74,
Identifiants
pubmed: 31258744
doi: 10.7150/jca.32909
pii: jcav10p2397
pmc: PMC6584346
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2397-2406Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Cancer Res. 1999 Aug 15;59(16):3915-8
pubmed: 10463582
Radiother Oncol. 2000 Oct;57(1):39-43
pubmed: 11033187
Mol Cell Biol. 2001 Jun;21(12):3862-75
pubmed: 11359895
Anal Cell Pathol. 2002;24(1):25-39
pubmed: 12122281
Br J Cancer. 2004 Mar 22;90(6):1222-9
pubmed: 15026805
Mol Cell Biol. 2004 Jul;24(13):6076-83
pubmed: 15199161
Anticancer Res. 2005 Jul-Aug;25(4):3109-16
pubmed: 16080574
Mol Cancer. 2010 Jun 01;9:133
pubmed: 20515450
Neurol Sci. 2013 Mar;34(3):365-71
pubmed: 22454035
Int J Oncol. 2012 Oct;41(4):1260-70
pubmed: 22825389
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6
pubmed: 23530248
Mol Biol Rep. 2013 Nov;40(11):6055-62
pubmed: 24057269
Neuro Oncol. 2015 Sep;17(9):1231-40
pubmed: 25681309
N Engl J Med. 2015 Jun 25;372(26):2499-508
pubmed: 26061753
Mol Cancer. 2015 Jul 17;14:134
pubmed: 26183089
Cancer Res. 1989 Dec 1;49(23):6449-65
pubmed: 2684393
Int J Clin Exp Med. 2015 Dec 15;8(12):22073-83
pubmed: 26885182
Front Oncol. 2016 Oct 24;6:222
pubmed: 27822457
Crit Rev Oncol Hematol. 2017 Dec;120:1-9
pubmed: 29198322
Neuro Oncol. 2018 Oct 9;20(11):1429-1438
pubmed: 29509936
Int J Nanomedicine. 2018 Oct 04;13:6049-6058
pubmed: 30323592
Front Oncol. 2018 Oct 23;8:464
pubmed: 30406030
Transl Cancer Res. 2016 Jun;5(Suppl 1):S54-S60
pubmed: 30680290
Science. 1994 Dec 23;266(5193):2011-5
pubmed: 7605428
Nature. 1996 Jan 4;379(6560):88-91
pubmed: 8538748
Cancer Res. 1996 Mar 1;56(5):941-3
pubmed: 8640781
Cancer Res. 1996 Oct 1;56(19):4509-15
pubmed: 8813149
Am J Physiol. 1996 Oct;271(4 Pt 1):C1172-80
pubmed: 8897823
Nat Genet. 1998 Jan;18(1):65-8
pubmed: 9425903
J Med Chem. 1998 Aug 13;41(17):3253-60
pubmed: 9703471
Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10188-93
pubmed: 9707622
Curr Opin Genet Dev. 1998 Oct;8(5):588-94
pubmed: 9794818
Int J Cancer. 1999 Jan 5;80(1):60-3
pubmed: 9935231